Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 27542767)

  • 1. A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas.
    Infante JR; Cassier PA; Gerecitano JF; Witteveen PO; Chugh R; Ribrag V; Chakraborty A; Matano A; Dobson JR; Crystal AS; Parasuraman S; Shapiro GI
    Clin Cancer Res; 2016 Dec; 22(23):5696-5705. PubMed ID: 27542767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors.
    Geoerger B; Bourdeaut F; DuBois SG; Fischer M; Geller JI; Gottardo NG; Marabelle A; Pearson ADJ; Modak S; Cash T; Robinson GW; Motta M; Matano A; Bhansali SG; Dobson JR; Parasuraman S; Chi SN
    Clin Cancer Res; 2017 May; 23(10):2433-2441. PubMed ID: 28432176
    [No Abstract]   [Full Text] [Related]  

  • 3. Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors.
    Tripathy D; Bardia A; Sellers WR
    Clin Cancer Res; 2017 Jul; 23(13):3251-3262. PubMed ID: 28351928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of single-agent ribociclib in Japanese patients with advanced solid tumors.
    Doi T; Hewes B; Kakizume T; Tajima T; Ishikawa N; Yamada Y
    Cancer Sci; 2018 Jan; 109(1):193-198. PubMed ID: 29059492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ribociclib, a selective cyclin D kinase 4/6 inhibitor, inhibits proliferation and induces apoptosis of human cervical cancer in vitro and in vivo.
    Xiong Y; Li T; Assani G; Ling H; Zhou Q; Zeng Y; Zhou F; Zhou Y
    Biomed Pharmacother; 2019 Apr; 112():108602. PubMed ID: 30784916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ribociclib (LEE011) suppresses cell proliferation and induces apoptosis of MDA-MB-231 by inhibiting CDK4/6-cyclin D-Rb-E2F pathway.
    Li T; Xiong Y; Wang Q; Chen F; Zeng Y; Yu X; Wang Y; Zhou F; Zhou Y
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):4001-4011. PubMed ID: 31588803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor pharmacokinetics and pharmacodynamics of the CDK4/6 inhibitor ribociclib in patients with recurrent glioblastoma.
    Miller TW; Traphagen NA; Li J; Lewis LD; Lopes B; Asthagiri A; Loomba J; De Jong J; Schiff D; Patel SH; Purow BW; Fadul CE
    J Neurooncol; 2019 Sep; 144(3):563-572. PubMed ID: 31399936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I or II Study of Ribociclib in Combination With Topotecan-Temozolomide or Everolimus in Children With Advanced Malignancies: Arms A and B of the AcSé-ESMART Trial.
    Bautista F; Paoletti X; Rubino J; Brard C; Rezai K; Nebchi S; Andre N; Aerts I; De Carli E; van Eijkelenburg N; Thebaud E; Corradini N; Defachelles AS; Ducassou S; Morscher RJ; Vassal G; Geoerger B
    J Clin Oncol; 2021 Nov; 39(32):3546-3560. PubMed ID: 34347542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study.
    Curigliano G; Gómez Pardo P; Meric-Bernstam F; Conte P; Lolkema MP; Beck JT; Bardia A; Martínez García M; Penault-Llorca F; Dhuria S; Tang Z; Solovieff N; Miller M; Di Tomaso E; Hurvitz SA
    Breast; 2016 Aug; 28():191-8. PubMed ID: 27336726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study.
    Abdul Razak AR; Bauer S; Suarez C; Lin CC; Quek R; Hütter-Krönke ML; Cubedo R; Ferretti S; Guerreiro N; Jullion A; Orlando EJ; Clementi G; Sand Dejmek J; Halilovic E; Fabre C; Blay JY; Italiano A
    Clin Cancer Res; 2022 Mar; 28(6):1087-1097. PubMed ID: 34921024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A selective cyclin-dependent kinase 4, 6 dual inhibitor, Ribociclib (LEE011) inhibits cell proliferation and induces apoptosis in aggressive thyroid cancer.
    Lee HJ; Lee WK; Kang CW; Ku CR; Cho YH; Lee EJ
    Cancer Lett; 2018 Mar; 417():131-140. PubMed ID: 29306020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Novel Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) Alone and in Dual-Targeting Approaches Demonstrates Antitumoral Efficacy in Neuroendocrine Tumors in vitro.
    Aristizabal Prada ET; Nölting S; Spoettl G; Maurer J; Auernhammer CJ
    Neuroendocrinology; 2018; 106(1):58-73. PubMed ID: 28226315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Kwapisz D
    Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual
    Wood AC; Krytska K; Ryles HT; Infarinato NR; Sano R; Hansel TD; Hart LS; King FJ; Smith TR; Ainscow E; Grandinetti KB; Tuntland T; Kim S; Caponigro G; He YQ; Krupa S; Li N; Harris JL; Mossé YP
    Clin Cancer Res; 2017 Jun; 23(11):2856-2868. PubMed ID: 27986745
    [No Abstract]   [Full Text] [Related]  

  • 15. Ribociclib for post-menopausal women with HR+/HER2- advanced or metastatic breast cancer.
    Zangardi ML; Spring LM; Blouin GC; Bardia A
    Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1169-1176. PubMed ID: 28875723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells.
    Reiter FP; Denk G; Ziesch A; Ofner A; Wimmer R; Hohenester S; Schiergens TS; Spampatti M; Ye L; Itzel T; Munker S; Teufel A; Gerbes AL; Mayerle J; De Toni EN
    Cell Oncol (Dordr); 2019 Oct; 42(5):705-715. PubMed ID: 31250364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer).
    Scheinberg T; Kench J; Stockler M; Mahon KL; Sebastian L; Stricker P; Joshua AM; Woo H; Thanigasalam R; Ahmadi N; Centenera MM; Butler LM; Horvath LG
    BMJ Open; 2020 Jan; 10(1):e033667. PubMed ID: 31988233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy of ribociclib as a first-line therapy for HR-positive, advanced breast cancer.
    Duso BA; Trapani D; Viale G; Criscitiello C; D'Amico P; Belli C; Mazzarella L; Locatelli M; Minchella I; Curigliano G
    Expert Opin Pharmacother; 2018 Feb; 19(3):299-305. PubMed ID: 29355400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ribociclib, a Cdk4/Cdk6 kinase inhibitor, enhances glucocorticoid sensitivity in B-acute lymphoblastic leukemia (B-All).
    Bortolozzi R; Mattiuzzo E; Trentin L; Accordi B; Basso G; Viola G
    Biochem Pharmacol; 2018 Jul; 153():230-241. PubMed ID: 29408328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ribociclib for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
    Burris HA
    Expert Rev Anticancer Ther; 2018 Mar; 18(3):201-213. PubMed ID: 29457921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.